Lancet Publication: New Analysis Demonstrates Only Small Minority of Severe/Very Severe COPD Patients May Benefit from Adding ICS to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) + LABA Therapy

• New post-hoc analysis shows routine eosinophil blood test could help identify the small minority   of severe/very severe patients who may benefit from addition of ICS* • Only 20 percent of patients in WISDOM† study benefited from addition of ICS on top of SPIRIVA®   HANDIHALER®‡ and a LABA§ with regards to exacerbation risk reduction • The data analysis, published in Lancet Respiratory Medicine, adds to current debate about appropriate   selection of patients for ICS treatment in chronic obstructive pulmonary disease (COPD)
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news